Skip to content
MarketScale
‹ Back to IndustriesSciences

The Hidden Roadblocks to Smarter Hospitals

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle. This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care. Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Ai in HospitalsAndrew LamkinBikram DayClinical Data
Share

Key takeaways

01

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle.

02

This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care.

03

Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day,…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle. This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care. Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day, Director of Informatics at Medical Informatics Corp., join Michelle Dawn Mooney to unpack the technical and clinical roadblocks buried deep in hospital systems today.

According to Day, the problem starts at the edge: “Most devices in the environment are not even connected. You end up with all that data going down a black hole.” Despite the availability of rich clinical data, fragmented device ecosystems and legacy workflows keep critical insights from reaching providers in time. Lamkin adds that while continuous monitoring has improved, infrastructure hasn’t kept pace with what’s possible: “Hospitals have networks and computing resources… we’re not talking about something that’s too high throughput to even start the conversation.”

The discussion emphasizes that many monitoring systems are still designed around outdated processes. “Almost all the infrastructure… has been there to replicate the manual charting,” Day explains. This manual-first mindset leads to hidden work for clinicians—connecting cables, hunting down data, and relying on telemetry stations that don’t scale. “We have way too many cables connecting things,” he says, but progress is happening with newer wireless sensors and shared protocols for devices like infusion pumps.

What’s needed to break through? Interoperability, automation, and rethinking the role of metadata. “Who, where, and when—all those factors are critical,” Day stresses, especially when preparing data for AI. Looking ahead, he calls for a mindset shift: “Use the human bandwidth for what the human is really good at… let the machines do their thing, which is crunching a whole bunch of data.”

Learn more about patient monitoring innovation by connecting with Andrew Lamkin and Bikram Day on LinkedIn, or by visiting Medical Informatics Corp. and Intel Health and Life Sciences.

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Network and Edge Solutions Group.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace forecasts more than 6,500 Earth observation satellites launching by 2035. It also projects $155.9 billion in manufacturing revenue, based on a SpaceNews-posted release dated Aug. 21, 2026. As defense-led demand shifts toward revisit rate and persistence, payload integration and fleet interoperability become the hard parts.

  • 01$155.9 billion is tied specifically to satellite manufacturing, not launch or ground, which should reshape how teams size supplier commitments and make-buy decisions.
  • 02Novaspace’s “skyscraper model” framing implies procurement power is shifting to payload integration, test capacity, and software-defined operations, even as the bus becomes more standardized.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512